TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06404125

Intervention type: DIAGNOSTIC_TEST
Intervention: Numeric Rating Scale
Description: Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain-Pressure Threshold Measurement With an Algometer
Description: The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral shoulder region and left forearm as control region and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~1. Bilateral supraspinatus muscle: 1 cm cranial to the midpoint of the spina scapulae~2. Bilateral infraspinatus muscle: Medial edge of the scapula, intersection of the spina scapula and the inferior scapular angle~3. Bilateral upper trapezius muscle: MidN point of the line joining the acromion and C7 spinous process~4. Left forearm volar face center as control point

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain-Pressure Threshold Measurement With an Algometer
Description: The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral shoulder region and left forearm as control region and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~1. Bilateral supraspinatus muscle: 1 cm cranial to the midpoint of the spina scapulae~2. Bilateral infraspinatus muscle: Medial edge of the scapula, intersection of the spina scapula and the inferior scapular angle~3. Bilateral upper trapezius muscle: MidN point of the line joining the acromion and C7 spinous process~4. Left forearm volar face center as control point
Study: NCT05675306

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Temporal and Tactile Cueing Treatment
Description: DTTC is a dynamic, motor-based treatment approach designed for children with severe CAS. This approach is based on Integral Stimulation (Edeal \& Gildersleeve-Neumann, 2011; Maas \& Farinella, 2012; Maas et al., 2019; Strand \& Debertine, 2000; Strand \& Skinder, 1999), in which the clinician instructs the child to listen to me, watch me, and do what I do and systematically taxes and supports the speech motor system to facilitate system-wide change in speech output (Strand, 2020).
Study: NCT05972083

Intervention type: DRUG
Group type: OTHER
Intervention: Analgesia management; group S and C
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia management; group S and C
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT05219045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ohio RETAIN
Description: RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an active comparator that is not.
Study: NCT06404125

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: This scale was developed by Zigmond and Snaith in 1983 to screen anxiety and depression in individuals with physical illness. The scale consists of fourteen questions, seven for anxiety and seven for depression, to be answered on a four-point Likert scale. The Turkish validity and reliability of the scale has been demonstrated and a score above ten for anxiety and seven for depression is considered significant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: This scale was developed by Zigmond and Snaith in 1983 to screen anxiety and depression in individuals with physical illness. The scale consists of fourteen questions, seven for anxiety and seven for depression, to be answered on a four-point Likert scale. The Turkish validity and reliability of the scale has been demonstrated and a score above ten for anxiety and seven for depression is considered significant.
Study: NCT05601999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-060
Description: GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Metalyse
Description: Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
Study: NCT05399628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter
Description: Participants will be assigned to perform the procedure with LISA catheter with a marked tip

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter
Description: Participants will be assigned to perform the procedure with LISA catheter with an unmarked tip
Study: NCT04717843

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4D Flow MRI
Description: Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D Flow MRI
Description: Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D Flow MRI
Description: Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical consultation with 12 leads ECG
Description: Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Holter ECG
Description: 48 hours ECG recording

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trans thoracic echocardiography
Description: Trans thoracic echocardiography with standard measures performes in the core lab.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard MRI
Description: Acquisitions of MR imagining
Study: NCT05756673

Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study: NCT05931562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented Foods
Description: Participants will recieve dietary education to include 4 to 6 portions of fermented foods to their normal diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fibre
Description: Participants will recieve dietary education to increase their fibre intake to 24-35g/day in their normal diet.
Study: NCT05756673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study: NCT05931562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Diet
Description: Participants will recieve dietary education to increase their fibre intake to 25-30g/day and include 3 to 4 portions of fermented foods to their normal diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will recieve dietary education based on the Irish healthy food pyramid.
Study: NCT06501300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-focused: Tuning in to Kids in School
Description: The aim of the TIKiS is to improve emotion coaching and reduce emotion dismissing in elementary school teachers through six x 90-minute group sessions.
Study: NCT06432998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal massage
Description: The technique will be applied for approximately twenty minutes and will be carried out as follows: the vaginal dilator is introduced progressively using crescent-shaped movements. Once the dilator is fully inserted, movements will be made from bottom to top and from one side to the other, and then continue with the crescent-shaped movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The treatment will consist of the use of vaginal dilators according to the gold standard proposed in the literature. It will consist of introducing the same dilators as for the experimental group, with the same time schedule, but without massage, only introducing the dilator and keeping it in the vagina for 20 minutes.
Study: NCT05756673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LISTERINE ZERO Alcohol Mouthwash COOL MINT
Description: Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LISTERINE ZERO Alcohol Mouthwash COOL MINT
Description: Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LISTERINE COOL MINT Antiseptic Mouthwash
Description: Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TePe Original Interdental Brush
Description: Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TePe Original Interdental Brush
Description: Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TePe Original Interdental Brush
Description: Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
Study: NCT05205954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hepatology Home Hospital
Description: The Hepatology Home Hospital intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with hepatology clinicians regarding care delivered at home to ensure continuity of care.
Study: NCT05066334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous BM-MSC
Description: intradiscal injection of autologous bone marrow mesenchymal stromal cells
Study: NCT06054737

Intervention type: PROCEDURE
Intervention: SPA THERAPY
Description: Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks~The balneotherapy sessions included:~* 10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression);~* 20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues);~* Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes
Study: NCT05066334

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: local anaesthesia, no disc injection, no placebo injection
Study: NCT04582812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training
Description: Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isolated inspiratory training
Description: Isolated high-intensity inspiratory muscle training during 8 weeks
Study: NCT06319144

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% glucose
Description: Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Patients in the control group were infused intravenously with 0.9% Normal Saline (500 ml/h) in the PACU.
Study: NCT04801901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dTRA
Description: Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fTRA
Description: Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
Study: NCT05725096

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Computed Tomography Angiography
Description: Intervention strategies according to CCTA results

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional cardiovascular risk stratification
Description: Intervention strategies according to traditional cardiovascular risk stratification based on Chinese guidelines for lipid management (2023)
Study: NCT03983837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neocate Splash
Description: Neocate Splash is a hypoallergenic, amino acid based elemental liquid diet that is taken orally.
Study: NCT05627661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosensor
Description: Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosensor
Description: Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
Study: NCT05878353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decontamination of the pocket with local doxycycline
Description: Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decontamination of the pocket with mechanical instrumentation
Description: Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
Study: NCT05873842

Intervention type: DEVICE
Intervention: Trans-femoral TAVI
Description: Trans-femoral TAVI (Trans-catheter Aortic Valve Implantation) with calcified ilio-femoral arteries via PTA (Percutaneous transluminal angioplasty ) or IVL (Intra-vascular Lithotripsy)

Intervention type: DEVICE
Intervention: Trans-femoral TAVI
Description: Trans-femoral TAVI (Trans-catheter Aortic Valve Implantation) with calcified ilio-femoral arteries via PTA (Percutaneous transluminal angioplasty ) or IVL (Intra-vascular Lithotripsy)
Study: NCT05955326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovateltide
Description: Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
Study: NCT03284437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Cognitive Training
Description: Choose level of activity (e.g., coloring, holding objects) based on occupational therapist assessment.
Study: NCT04882501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QUEASEEase aromatherapy quick tab
Description: Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
Study: NCT04090723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBI-CC with peer navigation
Description: Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
Study: NCT06581068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AURA assisted ART treatment
Description: The AURA device consists of five subsystems, which will operate in logical sequence to deliver comprehensive automation of the laboratory element of an ART cycle. The AURA treatment begins after ovarian stimulation, on the day of egg collection. A sperm sample is provided on the same day of egg collection. Sperm samples will be prepared by the C:SPERM subsystem. Follicular fluid obtained at egg collection will be processed by the C:EGG subsystem. 3 out of every 4 cumulus-oocyte complexes (COCs) recovered will be denuded by the C:EGG subsystem. These denuded eggs will be fertilized by the C:ICSI subsystem, incubated in the C:CULTURE subsystem and all resulting suitable embryos will be vitrified by the C:VIT subsystem. Thawed embryos may be used in conventional frozen embryo transfers.
Study: NCT05534087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX-FOLFIRI intensified chemotherapy
Description: (1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks~* Oxaliplatin 85mg/m2 IV infusion over 120 min D1~* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)~* Irinotecan 150mg/m2 IV infusion over 60-90 min D1~* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX or CAPOX adjuvant chemotherapy
Description: 1. FOLFOX regimen: 6 cycles every 2 weeks~   * Oxaliplatin 85mg/m2 IV infusion over 120 min D1~  * Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)~  * 5-fluorouracil 400mg/m2 IV bolus D1~  * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or~2. CAPOX regimen: 4 cycles every 3 weeks~   * Oxaliplatin 130mg/m2 IV infusion over 120 min D1~  * Capecitabine 1,000mg/m2 PO bid D1-14
Study: NCT06249893

Intervention type: OTHER
Intervention: Point-of-care vascular ultrasound
Description: Point-of-care ultrasound will be used to image the femoral vessels and to perform a pulsed-wave doppler measurement of blood flow during chest compressions and during pauses for rhythm and manual pulse checks.
Study: NCT04612790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.